Larvol Delta - Predictors-of-ASAS40-Response-to-Ivarmacitinib-in-Patients-with-Active-Ankylosing-Spondylitis-A-Posthoc-Analysis-of-a-Randomized-Doubleblind-Placebocontrolled-Phase-IIIII-Trial

AiSuDa (ivarmacitinib) - Jiangsu Hengrui Pharma, Arcutis

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1899450&mode=presInfo

Li Long, n/a

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next